BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Onyx Pharmaceuticals, Inc. (ONXX)'s Drug Candidates Might Attract Acquirers, CFO Says


1/13/2012 8:09:10 AM

Onyx Pharmaceuticals Inc., (ONXX) the developer of kidney cancer drug Nexavar, is an attractive target for acquirers because it may receive regulatory approvals for several new treatments during the next year, Chief Financial Officer Matt Fust said. Onyx was labeled the top biotechnology takeover target in 2012 in a survey last week by Mark Schoenebaum, an analyst with ISI Group in New York. The South San Francisco, California-based company was exploring options, including a potential sale process last year, two people familiar with the situation said in November.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES